GWave News
7 articles
growth-positive
HAGAR Secures $5 Million Funding for Non-Invasive Glucose Monitoring
HAGAR, the startup behind GWave, a non-invasive continuous glucose monitoring system, has secured a $5 million Series C funding round, bringing its total funding to $25 million. The startup showcased its latest clinical findings at the American Diabetes Association (ADA) conference. GWave offers real-time, precise blood glucose monitoring and features seamless Bluetooth and smartphone integration. The recent study demonstrated GWaves accuracy, especially during a glucose challenge. HAGAR plans to conduct more studies in the US and Israel and aims to incorporate the technology into smartwatches. The funding round was led by Columbia Pacific.
Investment
HAGAR Unveils New Clinical Data on Groundbreaking GWave Technology, Closing Round C Funding
growth-positive
Hagar showcases favorable GWave non-invasive blood glucose monitor data at ATTD following FDA breakthrough device designation
Israeli company HAGAR has showcased the encouraging study results of its GWave non-invasive blood glucose monitor at the Advanced Technologies and Treatments for Diabetes event. The glucometer, which utilizes radio frequency waves, demonstrated high accuracy and outperformed traditional finger-stick methods and continuous glucose monitors. The device has received a breakthrough device designation from the FDA and has attracted significant funding. HAGAR plans to conduct two more clinical studies later in the year. The second-generation GWave sensor is being designed to integrate with a smartwatch.
InvestmentCustomers
GWave by HAGAR to Present at Renowned Global Diabetes Conference
HAGAR GWave Awarded FDA Breakthrough Device Designation
growth-positive
Hagar Raises $11.7M in Series B Funding - FinSMEs
Hagar, a developer of non-invasive continuous glucose monitoring technology, has raised $11.7 million in Series B funding. This brings their total funding to $17.1 million. The funding will be used for upcoming trials for FDA approval and completing international patents. Hagars technology, called GWave, uses RF waves to measure glucose levels in the blood continuously. The company is led by General Guy Zur and Br. General Bentzi Gruber. The technology was conceived by Dr. Gerry Waintraub.
Investment
Wave of the Future: New Glucose Technology Could Revolutionize Care
